We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Michael Dabaie
Celgene Corp. (CELG) said the U.S. Food and Drug Administration approved Otezla 30 mg twice daily for adults with oral ulcers associated with Behcet's Disease.
Behcet's Disease is a rare, chronic, multisystem inflammatory disease that is difficult to treat, Celgene said. Otezla reduced the number and pain of oral ulcers in a 12-week placebo-controlled Phase 3 study.
Otezla is now approved for three indications in the U.S., including the treatment of patients with moderate to severe plaque psoriasis, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 19, 2019 14:32 ET (18:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
